ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Over 120 Drugs in developpement.

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Jun 04, 2024 5:04am

84 Views

Post# 36070535

RE:Over 120 Drugs in developpement.

Thanks for the link, very interesting POD's. Sounds like some very educated people on the panel. Promis should consider themself lucky to have Dr. Cohen on their SAB.

https://www.promisneurosciences.com/about/scientific-advisory-board

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?